You obviously don’t have a problem voicing your opinion. At least that’s the impression I got from reading the results of our first Life Science Leader email survey.
Nearly 100 people responded to our four-question survey, which included no multiple choice questions. That means everyone took the time to write out their answers to the following questions:
- What is the biggest struggle the pharma industry needs to overcome in the next year?
- What are the most important factors in selecting an outsourcing partner?
- What do you see as the best growth opportunities in the pharma and biopharma industries?
- How do you think the Pfizer/Wyeth merger will affect the industry?
Most of the respondents had titles such as CEO, president, managing partner, director, VP, chairman, or founder. For instance, John Tatum, VP at Myriad Pharmaceuticals, responded to the question about an outsourcing partner with “Dependability. All else pales in comparison to a reliable partner who promises conservatively and delivers without fail.” There were a lot of responses like this to that question, which is why in this issue on page 30 we included a roundtable discussion with six CROs discussing the future of the CRO-pharma relationship.
In the coming months, we plan to print more of this survey’s responses because we think you’ll find it valuable to see what your industry colleagues and peers are thinking. Furthermore, we plan to continue to use this type of feedback to guide some of our future editorial.
So keep those emails coming; I appreciate all of them — good or bad. And I thank everyone who took the time to comment on our first issue. In some future issue, I even hope to print some of your letters.